pipeline | autoimmune/inflammation | oncology
ALPN-101 is targeted to begin clinical studies in Q1-2019. ALPN-202 is targeted to enter the clinic in Q4-2019
Great weekend of data at #ASH18 for our ALPN-101 autoimmune/inflammatory disease program and our TIP/SIP technology… twitter.com/i/web/status/10695…
December 3, 2018 12:12 pm
Dr. Adom from @sophpacz Indiana University lab starting an #ASH18 oral presentation highlighting the underappreciat… twitter.com/i/web/status/10692…
December 2, 2018 5:30 pm
© 2018 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.